Readystate Asset Management LP Acquires 36,100 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Readystate Asset Management LP boosted its holdings in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 34.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 141,791 shares of the company’s stock after acquiring an additional 36,100 shares during the period. Readystate Asset Management LP owned about 0.40% of iTeos Therapeutics worth $1,553,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. GSA Capital Partners LLP bought a new position in iTeos Therapeutics during the 4th quarter worth about $519,000. Public Employees Retirement System of Ohio grew its holdings in iTeos Therapeutics by 55.1% during the 4th quarter. Public Employees Retirement System of Ohio now owns 37,186 shares of the company’s stock worth $407,000 after acquiring an additional 13,207 shares in the last quarter. Virtus ETF Advisers LLC grew its holdings in iTeos Therapeutics by 21.7% during the 4th quarter. Virtus ETF Advisers LLC now owns 8,596 shares of the company’s stock worth $94,000 after acquiring an additional 1,530 shares in the last quarter. Nuveen Asset Management LLC grew its holdings in iTeos Therapeutics by 222.9% during the 4th quarter. Nuveen Asset Management LLC now owns 193,401 shares of the company’s stock worth $2,118,000 after acquiring an additional 133,501 shares in the last quarter. Finally, Occudo Quantitative Strategies LP bought a new position in iTeos Therapeutics during the 4th quarter worth about $154,000. 97.16% of the stock is currently owned by institutional investors.

iTeos Therapeutics Trading Down 3.8 %

Shares of NASDAQ:ITOS traded down $0.42 during trading on Wednesday, reaching $10.68. The stock had a trading volume of 198,768 shares, compared to its average volume of 269,485. iTeos Therapeutics, Inc. has a one year low of $8.20 and a one year high of $18.24. The company has a market capitalization of $382.77 million, a P/E ratio of -3.39 and a beta of 1.19. The firm’s 50-day simple moving average is $11.40 and its 200 day simple moving average is $10.59.

iTeos Therapeutics (NASDAQ:ITOS) last posted its quarterly earnings results on Wednesday, March 6th. The company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.03) by $0.18. Equities research analysts forecast that iTeos Therapeutics, Inc. will post -4.76 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. HC Wainwright restated a “buy” rating and issued a $44.00 price target on shares of iTeos Therapeutics in a report on Thursday, March 7th. Wedbush restated an “outperform” rating and issued a $18.00 price target (down from $25.00) on shares of iTeos Therapeutics in a report on Wednesday, March 6th.

About iTeos Therapeutics

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.